(Times of Israel) A treatment for depression developed by Israeli start-up NeuroRx recently successfully completed a Phase II trial. Cuclurad produced a reduction of symptoms within two hours of treatment and those positive results lasted for over eight weeks. Dr. Jonathan Javitt, founder and CEO of NeuroRx, said, "When someone dies from cancer, we blame the disease and look for a cure. Even though suicide is driven by chemical pathways in the brain, when people die of this disease, we tend to blame the patient. Our mission is to develop a first-class lifesaving drug for an unmet medical need, specifically suicide and depression." "Suicide has long been viewed as an end stage of depression, when in fact it's a distinct medical entity that appears to be driven by different brain pathways than those that drive depression. Every anti-depressive drug on the market today is known to increase the risk for suicide."
2016-05-27 00:00:00Full ArticleBACK Visit the Daily Alert Archive